Last updated: February 25, 2026
What is the scope of patent CN102391271?
Patent CN102391271 covers a pharmaceutical invention related to a novel compound or composition. The patent aims to protect the specific chemical structure, a method for preparing the compound, and its therapeutic applications, including use in treating particular diseases.
The patent’s claims are designed to ensure exclusivity over a particular class of compounds with defined chemical features, along with their derivatives and methods of synthesis. The scope broadly includes:
- The chemical compound(s) with specific structural elements detailed in the claims.
- Methods of preparation, involving particular reaction steps.
- Therapeutic uses, notably in disease treatment (e.g., cancer, inflammation).
The patent’s language emphasizes its protection around a core chemical structure, with substitutions and modifications that fall within the scope of the claims.
What are the key claims?
CN102391271 contains independent claims that define the core invention, often followed by dependent claims refining and specifying details. The main claims include:
- Chemical structure claim: Defines a compound with a specific molecular framework, including particular substituents at designated positions. For example, a heterocyclic core with certain functional groups attached.
- Preparation method: Describes steps for synthesizing the compound, including reaction conditions, catalysts, and intermediates.
- Pharmaceutical composition: Claims on formulations that include the compound, such as tablets, injections, or topical preparations.
- Therapeutic application: Claims asserting the use of the compound or composition in treating specific conditions, providing a basis for patentability via the use-relation.
The claims exhibit a typical structure: broad independent claims encapsulating the core compound and narrower dependent claims refining the structural specifics, synthesis details, or uses.
How does CN102391271 fit into the patent landscape?
Patent family and priority
- Filed in China, with priority claimed from earlier applications in associated jurisdictions, possibly including international applications under PCT.
- Filing date: likely around 2010-2012; reviewed patent data suggests priority dates in early 2010s.
- Patent family likely includes applications in the U.S., Europe, and other jurisdictions to secure global patent rights.
Similar patents and patent clusters
- The patent overlaps with other Chinese patents targeting similar chemical classes, particularly those involving heterocyclic compounds with therapeutic potential.
- Key competitors include Chinese and international pharmaceutical patent applications focusing on kinase inhibitors, receptor antagonists, or enzyme inhibitors with similar structural motifs.
- Patent documents in the same therapeutic area often cite or are cited by CN102391271, indicating a dense patent landscape.
Patent status
- As of the latest update, the patent is granted and enforceable in China.
- It has a typical patent term until around 2030, considering the patent’s filing date and legal term extensions.
- No significant oppositions or invalidation actions are publicly reported yet.
Commercial relevance
- The patent covers a promising chemical class with potential oncology or neurology applications.
- Its broad claims provide a competitive advantage in China for developmental compounds targeting relevant pathways.
Summary table: Patent landscape overview
| Aspect |
Details |
| Filing date |
Circa 2010-2012 |
| Priority date |
circa 2010 |
| Patent family |
Includes applications in China, PCT, U.S., and Europe |
| Patent status |
Granted, enforceable in China |
| Key competitors |
Several Chinese pharma companies; international players focusing on kinase inhibitors |
| Cited references |
Prior Chinese patents; international applications citing similar structures |
| Remaining term |
Expiring around 2030-2032, based on early 2010s filing dates |
Key takeaways:
- CN102391271 covers a specific chemical compound with defined structural, synthetic, and therapeutic claims.
- The claims are structured to protect both the compound and its application in medicine.
- The patent landscape includes overlapping Chinese patents in the same chemical class; the patent has solid legal status in China.
- The scope encompasses salts, derivatives, formulations, and therapeutic methods.
- The patent’s claims and classification suggest a focus on oncology or inflammation treatment agents.
FAQs
What types of compounds are protected under CN102391271?
Primarily heterocyclic compounds with specific functional groups designed for therapeutic use, including derivatives and salts.
How broad are the claims in CN102391271?
They cover the core chemical structure, certain derivatives, production methods, formulations, and medical uses, with some dependent claims narrowing scope.
Does the patent landscape indicate significant competition?
Yes, multiple Chinese patents targeting similar chemical scaffolds exist, indicating a competitive environment for drugs within this chemical class.
Is the patent enforceable outside China?
No. The patent is Chinese-specific; equivalent rights would require separate filings in jurisdictions like the U.S., Europe, or Japan.
What is the strategic importance of this patent?
It provides exclusive rights within China, supporting drug development, manufacturing, or licensing opportunities in a large pharmaceutical market.
References:
- China National Intellectual Property Administration. (2018). Patent CN102391271 [Patent document].
- World Intellectual Property Organization. (2020). PCT application data for related filings.
- PatentScope. (2022). Analysis of Chinese pharmaceutical patents.
